Program Highlights and Upcoming Events from the Cancer Center
CHOP is No. 1 on Forbes’ 2022 list of America’s Best Large Employers! We have open positions including:
- Hospital Physician - Inpatient Pediatric Oncology / Stem Cell Transplant
- Hospital Physician - Pediatric Oncology / Stem Transplant (Inpatient and Outpatient)
Resources for professionals and referring providers
Refer a patient to the Cancer Center: One of our oncologists will work with you to determine the next best steps in the child's care and answer any questions you may have.
Second opinions: We work with families and pediatric specialists from all over the country and around the world to confirm diagnoses or to provide second opinions.
Subscribe to our email list: Sign up to receive oncology-specific information for professionals right in your inbox.
Connect with us on Twitter: Follow us on Twitter to receive updates.
Experts from CHOP’s Cancer Center lead webinars on oncology and oncology-related topics, discussing the latest in cancer research and care. View the archive.
- CHOP Researchers Uncover Unique Mechanism for Cancer Therapy Resistance
- Children’s Hospital of Philadelphia Establishes the Susan S. and Stephen P. Kelly Center for Cancer Immunotherapy
- CHOP Brings Together Experts to Discuss Precision Medicine in Pediatric Cancer Care
- CHOP Researchers Refine Experimental Prodrug Treatment of High-Risk Neuroblastoma
- CHOP-Led Study Finds Bortezomib Improves Survival in Children with Newly Diagnosed T-Cell Lymphoblastic Lymphoma
- CHOP Study Shows Chemotherapy-Resistant Neuroblastoma Cells Have More Active Inflammatory Sensing and Signaling
- CHOP/Penn Study Shows CAR-T Cells Remain Active a Decade After Infusion
Comprehensive Vascular Anomalies Program (CVAP)
Patients with vascular anomalies have conditions of the veins, arteries and the lymphatic system that can be classified as tumors (benign and malignant) and vascular malformations (congenital anomalies of the vasculature). These conditions, which can range in complexity, can cause pronounced visible deformities and disfigurement, impede critical organ functions such as swallowing or breathing, or cause severe pain interfering with one’s quality of life. The CVAP at Children’s Hospital of Philadelphia (CHOP) includes state-of-the-art genomics and personalized research strategies to determine the causes of these conditions and identify targeted therapies. These innovative options are based on standards of excellent interdisciplinary clinical care.
Cancer Immunotherapy Program
Children with certain cancers and other disorders of the blood and immune system may benefit from cellular immunotherapy at Children’s Hospital of Philadelphia (CHOP). Doctors at Children's Hospital were the first to begin offering cell therapy in pediatrics as part of a pilot study in 2012. Our doctors and researchers helped develop the first national and international clinical trials for an immunotherapy known as chimeric antigen receptor (“CAR”) T-cell therapy for children with advanced acute lymphoblastic leukemia (ALL). CAR T-cell therapy for B-cell ALL was the first-ever cell therapy to receive FDA approval. Stephan Grupp, MD, PhD, Chief of the Cellular Therapy and Transplant Section at CHOP, was the lead investigator for the global trial led by Novartis.
Learn more about Cancer Immunotherapy Program.
Pediatric Proton Therapy Center
For your child with cancer, you choose treatments not just because they are effective but because they are safe and limit long-term effects. Proton therapy’s greatest benefit is the ability to deliver radiation doses directly to your child’s tumors, minimizing damage to surrounding healthy tissue. The Cancer Center at Children's Hospital of Philadelphia (CHOP) offers one of the most established and experienced pediatric proton therapy programs, in collaboration with Penn Medicine at the Roberts Proton Therapy Center. It was the first facility of its kind, designed specifically with children in mind.
Learn more about the Pediatric Proton Therapy Center.
Cancer Predisposition Program
About 16,000 children under the age of 20 are diagnosed with cancer each year in the United States, and researchers now estimate that at least 10 percent of childhood cancers have a hereditary basis. To harness the growing understanding of hereditary factors in childhood cancer, we created the Cancer Predisposition Program in 2005. CHOP’s program uses the latest advances in technology to provide genetic testing, genetic counseling and cancer surveillance, and thus improve the outlook for children with a genetic predisposition to develop cancer.
Learn more about the Cancer Predisposition Program
Very Rare Malignant Tumors Program
Children with very rare malignant tumors will find unparalleled expertise in the multidisciplinary team at the Very Rare Malignant Tumors Program. These tumors come in different forms and are individually very rare, but as an aggregate, they comprise more than 10% of all pediatric cancers. Our program will give these patients a pediatric medical home and also drive discoveries in these often under-researched types of cancers.
Learn more about Very Rare Malignant Tumors Program
Oncology Psychosocial Services Services Program
The Oncology Psychosocial Services Program is staffed by an expert team of psychologists, social workers, child-life specialists, creative arts therapists, chaplains and teachers who support cancer patients, families and medical staff at CHOP.
Learn more about our Psychosocial Services Services Program.
CHOP's Cancer Center is a pediatric cancer treatment facility staffed by internationally recognized pediatric oncologists and teams with expertise in every type of pediatric cancer. Our physicians, who have expertise in the rarest and most common pediatric cancers, work together to diagnose and treat patients using an evidence-based approach backed by the latest research advancements.